Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Zhejiang Conba Pharmaceutical Co's OCF Margin % or its related term are showing as below:
SHSE:600572'
s OCF Margin % Range Over the Past 10 Years
Min: 7.83 Med: 14.12 Max: 21.15
Current: 15.13
During the past 13 years, the highest OCF Margin % of Zhejiang Conba Pharmaceutical Co was 21.15%. The lowest was 7.83%. And the median was 14.12%.
SHSE:600572's OCF Margin % is ranked better than 65.77% of 964
companies
in the Drug Manufacturers industry
Industry Median: 10.035
vs SHSE:600572: 15.13
Zhejiang Conba Pharmaceutical Co OCF Margin % Related Terms
Zhejiang Conba Pharmaceutical Co OCF Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zhejiang Conba Pharmaceutical Co OCF Margin % Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Zhejiang Conba Pharmaceutical Co's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zhejiang Conba Pharmaceutical Co OCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Zhejiang Conba Pharmaceutical Co's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Zhejiang Conba Pharmaceutical Co's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zhejiang Conba Pharmaceutical Co (SHSE:600572) has a OCF Margin % of 11.59% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Zhejiang Conba Pharmaceutical Co and its competitors. This is 18% below median its historical median of 14.12. Over the past decade, Zhejiang Conba Pharmaceutical Co's OCF Margin % has ranged from 7.83 to 21.15. According to the industry distribution chart, Zhejiang Conba Pharmaceutical Co ranks #330 out of 964 companies in the Drug Manufacturers industry, placing it in the top 34.2%.
Is Zhejiang Conba Pharmaceutical Co's OCF Margin % too high?
Zhejiang Conba Pharmaceutical Co's current OCF Margin % of 11.59% is 18% below median its 10-year median of 14.12. Over the past 10 years, this metric has ranged from a low of 7.83 to a high of 21.15. The Drug Manufacturers industry median OCF Margin % is 10.04. Zhejiang Conba Pharmaceutical Co's value of 11.59% is 15.5% above this industry median. Based on the distribution chart, Zhejiang Conba Pharmaceutical Co ranks #330 out of 964 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Zhejiang Conba Pharmaceutical Co has a GF Score™ of 71/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Zhejiang Conba Pharmaceutical Co's OCF Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Zhejiang Conba Pharmaceutical Co ranks #330 out of 964 companies for OCF Margin %. This puts Zhejiang Conba Pharmaceutical Co in the upper half of its industry. The industry median OCF Margin % is 10.04. Zhejiang Conba Pharmaceutical Co's value of 11.59% is 15.5% above this benchmark. Historically, Zhejiang Conba Pharmaceutical Co's own OCF Margin % has ranged from 7.83 to 21.15 over the past decade. While the company's 10-year median is 14.12 vs. the industry median of 10.04, Zhejiang Conba Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Drug Manufacturers company?
The median OCF Margin % among Drug Manufacturers companies is 10.04, based on 964 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zhejiang Conba Pharmaceutical Co's current OCF Margin % of 11.59% is 15.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Zhejiang Conba Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median OCF Margin % is 10.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zhejiang Conba Pharmaceutical Co's current OCF Margin % is 11.59%, which is 18% below median its own 10-year median of 14.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhejiang Conba Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Zhejiang Conba Pharmaceutical Co (SHSE:600572) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥5.51, compared to a current price of ¥4.32 — trading 21.6% below its estimated fair value. The current OCF Margin % is 11.59%, which is 18% below median its 10-year median of 14.12 and 15.5% above the Drug Manufacturers industry median of 10.04. Zhejiang Conba Pharmaceutical Co's overall GF Score™ is 71/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Zhejiang Conba Pharmaceutical Co (SHSE:600572), the current OCF Margin % is 11.59% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zhejiang Conba Pharmaceutical Co (SHSE:600572) Overvalued in 2026?
Based on GuruFocus' analysis, Zhejiang Conba Pharmaceutical Co stock appears to be undervalued.
The current stock price of ¥4.32 is trading 21.6% below its estimated GF Value™ of ¥5.51.
GuruFocus considers Zhejiang Conba Pharmaceutical Co to be Modestly Undervalued.
Key valuation signals for SHSE:600572:
OCF Margin %: 11.59% (18% below median its 10-year median of 14.12)
GF Value™: ¥5.51 vs. price of ¥4.32 (21.6% below fair value)
Industry Position: 15.5% above the Drug Manufacturers median (#330 of 964)
No single metric tells the full story. See the SHSE:600572 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zhejiang Conba Pharmaceutical Co Business Description
Zhejiang Conba Pharmaceutical Co Ltd operates as a pharmaceutical company in China. It offers traditional Chinese medicines, botanical extracts, chemical medicines, chemical raw medicines, health foods, common foods, prepared drugs in pieces, and commodities. It provides its products under the Conba, Prostate Plus, Zhenshiming, Tianbaoning, Alocin, Xitao, Yuanbang, Baby, and Omeprazole names.
71GF Score
Get the complete analysis for SHSE:600572
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600572 has been successfully added to your 
